2017 Mack Lecture: Professor David MacMillan
Dave MacMillan was born in Bellshill, Scotland and received his undergraduate degree in chemistry at the University of Glasgow, where he worked with Dr. Ernie Colvin. In 1990, he began his doctoral studies under the direction of Professor Larry Overman at the University of California, Irvine, before undertaking a postdoctoral position with Professor Dave Evans at Harvard University (1996). He began his independent career at University of California, Berkeley in July of 1998 before moving to Caltech in June of 2000 (Earle C. Anthony Chair of Organic Chemistry). In 2006, Dave moved to the east coast of the US to take up the position of James S. McDonnell Distinguished University Professor at Princeton University and he served as Department Chair from 2010-15. To date he has trained nearly 200 co-workers (55 graduate students, 145 postdoctoral coworkers), and has placed over 40 members of his group into academia around the world.
Dave has received several awards including the Janssen Pharmaceutica Prize (2016), Max Tischler Prize Harvard (2016), Ernst Schering Award in Biology, Chemistry and Medicine, Germany (2015), ACS Harrison Howe Award (2014), NJ ACS Molecular Design Award (2014), ACS Award for Creativity in Synthesis (2011), the Mitsui Catalysis Award (2011), ACS Cope Scholar Award (2007), ACS EJ Corey Award (2005), the Corday-Morgan Medal (2005).
In 2012 Dave became a Fellow of the Royal Society (FRS) and a Fellow of the American Academy of Arts and Sciences.
Dave helped launch and was editor-in-chief of Chemical Sciences (2009-2014) and is currently Chair of the NIH Study Section SBCA.
Dave is a scientific consultant with Merck (worldwide), Amgen (worldwide), Biogen Biopharma, Abbvie Research Laboratories, Takeda Pharmaceuticals, Johnson & Johnson Pharmaceuticals, UCB-Celtech, Constellation Pharmaceuticals and Gilead Research Laboratories. Dave is also a member of the scientific advisory boards of Firmenich (Switzerland) and Kadmon Pharmaceuticals (US), and a permanent member of the RSRC board at Merck Research Laboratories.
Along with Dr. Paul Reider, Dave is a co-founder of Chiromics LLC, a growing biotech that seeks to devise new strategies and screening techniques for the identification of drug-like molecules.
March 9, 2017 - 4:30pm, CBEC 130 "Why does the world need new chemistry and new catalysts?"
March 10, 2017 - 11:30am, MP 1015 "New Photoredox Reactions"
The Edward Mack, Jr. Lectures
Professor Edward Mack, Jr. was a long time faculty member of the Chemistry Department at The Ohio State University. After fourteen years as chairman, he resigned in October, 1955, to be devoted full time to teaching and research. Not long thereafter his friends and former students learned of his death in June, 1956.